X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs AUROBINDO PHARMA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS AUROBINDO PHARMA NOVARTIS/
AUROBINDO PHARMA
 
P/E (TTM) x 388.4 15.9 2,436.3% View Chart
P/BV x 19.1 4.1 467.2% View Chart
Dividend Yield % 1.5 0.4 395.8%  

Financials

 NOVARTIS   AUROBINDO PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-16
AUROBINDO PHARMA
Mar-17
NOVARTIS/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs982895 109.7%   
Low Rs556622 89.4%   
Sales per share (Unadj.) Rs252.9254.6 99.3%  
Earnings per share (Unadj.) Rs62.139.3 158.2%  
Cash flow per share (Unadj.) Rs63.346.6 135.9%  
Dividends per share (Unadj.) Rs10.002.50 400.0%  
Dividend yield (eoy) %1.30.3 394.5%  
Book value per share (Unadj.) Rs363.6160.0 227.3%  
Shares outstanding (eoy) m31.96585.88 5.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.03.0 102.1%   
Avg P/E ratio x12.419.3 64.1%  
P/CF ratio (eoy) x12.216.3 74.6%  
Price / Book Value ratio x2.14.7 44.6%  
Dividend payout %16.16.4 252.8%   
Avg Mkt Cap Rs m24,580444,390 5.5%   
No. of employees `0000.814.0 5.4%   
Total wages/salary Rs m1,80117,678 10.2%   
Avg. sales/employee Rs Th10,748.910,667.8 100.8%   
Avg. wages/employee Rs Th2,395.21,264.3 189.4%   
Avg. net profit/employee Rs Th2,641.11,645.8 160.5%   
INCOME DATA
Net Sales Rs m8,083149,157 5.4%  
Other income Rs m8291,159 71.6%   
Total revenues Rs m8,913150,316 5.9%   
Gross profit Rs m23434,343 0.7%  
Depreciation Rs m374,276 0.9%   
Interest Rs m2667 0.3%   
Profit before tax Rs m1,02530,558 3.4%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m170-   
Extraordinary Inc (Exp) Rs m1,6960-   
Tax Rs m7527,597 9.9%   
Profit after tax Rs m1,98623,012 8.6%  
Gross profit margin %2.923.0 12.6%  
Effective tax rate %73.424.9 295.1%   
Net profit margin %24.615.4 159.3%  
BALANCE SHEET DATA
Current assets Rs m12,67892,062 13.8%   
Current liabilities Rs m2,43366,223 3.7%   
Net working cap to sales %126.717.3 731.6%  
Current ratio x5.21.4 374.8%  
Inventory Days Days33106 30.9%  
Debtors Days Days2268 33.2%  
Net fixed assets Rs m6962,919 0.1%   
Share capital Rs m160586 27.3%   
"Free" reserves Rs m11,46093,133 12.3%   
Net worth Rs m11,62193,719 12.4%   
Long term debt Rs m01,814 0.0%   
Total assets Rs m14,400162,494 8.9%  
Interest coverage x570.546.8 1,219.0%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.9 61.2%   
Return on assets %13.814.6 94.7%  
Return on equity %17.124.6 69.6%  
Return on capital %23.632.7 72.0%  
Exports to sales %0.70-   
Imports to sales %18.60-   
Exports (fob) Rs m60NA-   
Imports (cif) Rs m1,503NA-   
Fx inflow Rs m18675,838 0.2%   
Fx outflow Rs m1,82130,224 6.0%   
Net fx Rs m-1,63545,613 -3.6%   
CASH FLOW
From Operations Rs m2,53132,786 7.7%  
From Investments Rs m-8,270-17,870 46.3%  
From Financial Activity Rs m-386-19,153 2.0%  
Net Cashflow Rs m-6,125-4,239 144.5%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 8.0 25.2%  
FIIs % 1.6 27.7 5.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 10.2 210.8%  
Shareholders   41,647 69,601 59.8%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   ALKEM LABORATORIES  PLETHICO PHARMA  GLENMARK PHARMA  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Idea Plunges 5% on Weak Q3 Peformance(Closing)

Indian share markets finished on a flat note after a five-session record-setting spree as profit booking was witnessed in metal stocks, capital goods stocks.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jan 24, 2018 03:33 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS